Supreme Court Will Hear Patent Infringement Dispute Over “Skinny Label”

In January of 2026, Reuters reported that the Supreme Court of the United States agreed to hear a patent infringement case over a so-called “skinny label.” The controversy in question is centered around the drug Vascepa. The case is Hikma v. Amarin. Within this article, our Florida patent infringement attorney provides a more comprehensive review and evaluation of the case.

Background: What a Skinny Label Means in Patent Law

A “skinny label” comes out of the Hatch-Waxman pathway for generic drugs. When a brand drug has multiple FDA-approved indications and only some of those uses are covered by method-of-use patents listed in the Orange Book, a generic manufacturer can pursue approval for the unpatented use while carving out the patented use from its labeling. The legal premise is narrow: the generic seeks approval only for the non-patented indication. For that reason, it does not “infringe” by proposing a label that omits the patented use. 

Case Review: Hikma v. Amarin

Amarin sells a pharmaceutical drug called Vascepa (icosapent ethyl). Notably, this particular drug has an older indication for severe hypertriglyceridemia and for later cardiovascular risk-reduction indication tied to method-of-use patents. Hikma, a competing company, sought to launch a generic for the older, unpatented use. The company wanted to use the “skinny label” route in order to carve out the patented cardiovascular indication. Amarin sued to block it.

Amarin’s claim does not hinge on Hikma’s label reciting the patented use verbatim. Instead, its theory is focused on alleged induced infringement under 35 U.S.C. § 271(b). Amarin contends that Hikma took affirmative steps that encouraged prescribing and dispensing for the patented cardiovascular use even though the generic’s FDA-approved label carved that use out. The allegations focused on external communications and marketing conduct, not just the FDA label text.

The Bottom Line: The patent dispute in this case does not focus on whether or not Hikma copied the patented indication. Instead, the question is: did Hikma, despite the carve-out, actively encourage the patented method-of-use through how it described and promoted its product into a substitution-driven market.

What the Supreme Court Is Being Asked to Decide and Why It Matters

The Supreme Court agreed in January 2026 to review where the liability boundary sits when a generic uses a skinny label but markets into a system where off-label prescribing and automatic substitution are foreseeable. The central legal question is how to apply 35 U.S.C. § 271(b) in the Hatch-Waxman carve-out context. More specifically, the Court is poised to address what counts as “encouragement” and “intent” when the label omits the patented indication, but the product is still positioned as the branded drug’s generic equivalent in ordinary commercial channels. In other words, this is a technical patent issue, but one that is very important for the industry. 

Contact Our South Florida Patent Infringement Lawyer Today

At Perkins Law — Brand Protection, our Florida IP lawyer has the experience to handle patent infringement cases. If you have any questions about a patent dispute, we are here as a legal resource. Contact us now for a fully confidential, no obligation initial consultation. From our Boca Raton office, we handle patent infringement cases throughout South Florida.

Source:

reuters.com/legal/litigation/us-supreme-court-hear-skinny-label-patent-fight-involving-amarin-2026-01-16/